Progress (PRGS) (SGEN) (AMLN) (RCII) (RMBS) (TTWO) Ratings, Price Targets

Progress Software (NASDAQ: PRGS), Seattle Genetics, Inc. (NASDAQ: SGEN), Amylin Pharma (NASDAQ: AMLN), Rent-A-Center, Inc. (NASDAQ: RCII), Rambus Inc. (NASDAQ: RMBS) and Take-Two (NASDAQ: TTWO) ratings and price targets.

Progress Software (PRGS) had its “Buy” rating reiterated by Needham & Company.

Seattle Genetics, Inc. (SGEN) had its “Sell” rating reiterated by Canaccord Genuity.

Amylin Pharma (AMLN) is now covered by Rodman & Renshaw. They placed an “Underperform” rating and a price target of $8.00 on the company.

Rent-A-Center, Inc. (NASDAQ: RCII) had its “Neutral” rating reiterated by Zacks Investment Research. They have a price target of $39.00 on the company.

Rambus Inc. (RMBS) had its “Neutral” rating reiterated by JPMorgan Chase & Co. (NYSE:JPM). They have a price target of $11.50 on the company.

Take-Two (TTWO) was upgraded by MKM Partners from a “Neutral” rating to a “Buy” rating. They have a price target of $20.00 on the company, up from $16.00.

Celldex (CLDX) (SGEN) (SHOO) (SLF) (CCI) (CE) Ratings, Price Targets

Celldex Therapeutics Inc (CLDX), Seattle Genetics, Inc. (SGEN), Steven Madden, Ltd. (SHOO), Sun Life Financial Inc. (SLF), Crown Castle (CCI) and Celanese Co. (CE) ratings and price targets.

Jefferies (NYSE:JEF) reiterated its “Buy” rating on Seattle Genetics, Inc. (SGEN). They have a price target of $28.00 on the company.

Canaccord Genuity initiated coverage on Steven Madden, Ltd. (SHOO). They placed a “Buy” rating and a price target of $47.00 on the company.

Morgan Stanley (NYSE:MS) initiated coverage on Sun Life Financial Inc. (SLF). They placed an “Equal Weight” rating on the company.

Macquarie initiated coverage on Crown Castle (CCI). They placed an “Outperform” rating on the company.

Gilford Securities reiterated its “Hold” rating on Celanese Co. (CE).

Jefferies initiated coverage on Celldex Therapeutics Inc (CLDX). They placed a “Buy” rating and a price target of $4.00 on the company.

Opko (OPK) (PCYC) (PXP) (QEP) (RF) (SGEN) (WMS) Get New Coverage

Opko Health Inc. (NYSE: OPK), Pharmacyclics, Inc. (NASDAQ: PCYC), Plains Exploration & Production Company (NYSE: PXP), QEP Resources (NYSE: QEP), Regions Financial Corp. (NYSE: RF), Seattle Genetics, Inc. (NASDAQ: SGEN) and WMS Industries Inc. (NYSE: WMS) getting new coverage from analysts.

Jefferies (NYSE:JEF) initiated coverage on Opko Health Inc. (OPK). They placed a “Buy” rating on the company.

Needham & Company initiated coverage on Pharmacyclics, Inc. (PCYC). They placed a “Buy” rating and a price target of $14.00 on the company.

KeyBanc initiated coverage on Plains Exploration & Production Company (PXP). They placed a “Buy” rating and a price target of $45.00 on the company.

Raymond James (NYSE:RJF) initiated coverage on QEP Resources (QEP). They placed an “outperform” rating and a $47.00 price target on the company.

BMO Capital Markets initiated coverage on Regions Financial Corp. (RF). They placed an “Outperform” rating on the company.

Needham & Company initiated coverage on Seattle Genetics, Inc. (SGEN). They placed a “Buy” rating and a price target of $20.00 on the company.

Nomura initiated coverage on WMS Industries Inc. (WMS). They placed a “Neutral” rating on the company.

Lear (LEA) (TTMI) (MCHP) (CBOE) (SFY) (SGEN) Price Targets Changed

Lear Co. (NYSE: LEA), TTM Tech (NASDAQ: TTMI), Microchip Technology Inc. (NASDAQ: MCHP), CBOE Holdings, Inc (NASDAQ: CBOE), Swift Energy (NYSE: SFY) and Seattle Genetics, Inc. (NASDAQ: SGEN) price targets adjusted by analysts.

Lear Co. (NYSE: LEA) had its price target raised by Barclays Capital to $67.00. They have an “Overweight” rating on the company.

TTM Tech (TTMI) had its price target lowered by UBS AG from $20.00 to $17.00. They have a “Buy” rating on the company.

Microchip Technology Inc. (MCHP) had its price target lowered by UBS AG (NYSE:UBS) from $37.00 to $33.50. They have a “Neutral” rating on the company.

CBOE Holdings, Inc. (CBOE) had its price target raised by Barclays Capital to $26.00. They have an “Equal Weight” rating on the company.

Swift Energy (SFY) had its price target lowered by MKM Partners from $52.00 to $46.00. They have a “Buy” rating on the company.

Seattle Genetics, Inc. (SGEN) had its price target lowered by UBS AG from $21.00 to $16.00. They have a “Neutral” rating on the company.

Marriott (MAR) (MRVL) (MXL) (RAH) (SGEN) Price Targets Changed

Marriott (NYSE: MAR), Marvell Technology Group (NASDAQ: MRVL), MaxLinear Inc (NYSE: MXL), Ralcorp Holdings, Inc. (NYSE: RAH) and Seattle Genetics, Inc. (NASDAQ: SGEN) price targets changed.

Marriott (MAR) had its price target lowered by Rodman & Renshaw from $43.00 to $38.00. They have a “market perform” rating on the company.

Marvell Technology Group (MRVL) had its price target lowered by Needham & Company from $22.50 to $19.50. They have a “buy” rating on the company.

MaxLinear Inc (MXL) had its price target lowered by analysts at

Needham & Company from $13.00 to $11.00. They have a “buy” rating on the company.

Ralcorp Holdings, Inc. (RAH) had its price target lowered by Longbow Research from $98.00 to $95.00. They have a “buy” rating on the company.

Seattle Genetics, Inc. (SGEN) had its price target raised by Oppenheimer from $21.00 to $24.00. They have an “outperform” rating on the company.

Price Targets on (TJX) (SQI) (SGEN) (PRO) (PPO) Updated

Analysts updated their price targets on TJX Companies Inc (NYSE: TJX), Sciquest Incorporated (NYSE: SQI), Seattle Genetics, Inc. (NASDAQ: SGEN), PROS Holdings, Inc. (NYSE: PRO) and Polypore (NYSE: PPO) today.

Avondale Partners raised their price target on TJX Companies Inc (TJX) from $55.00 to $61.00.

Northland Securities raised their price target on PROS Holdings, Inc. (PRO) from $17.00 to $19.00. They now have an “outperform” rating on the company.

Ardour Capital raised their price target on shares of Polypore (PPO) from $68.00 to $80.00. They have a “buy” rating on the company.

Needham & Company raised their price target on Seattle Genetics, Inc. (NASDAQ: SGEN) from $18.00 to $22.00. They have a “buy” rating on the company.

Stifel Nicolaus raised their price target on shares of Sciquest Incorporated (SQI) from $16.00 to $18.00. They have a “buy” rating on the company.

Seattle Genetics (NASDAQ:SGEN) Approval Risk of B. Vedotin Lowering

Citing the quality of the data surrounding the approval process of Seattle Genetics' (NASDAQ:SGEN) b. vedotin, Needham sees the risk being lowered for approval.

Needham said, "We believe SGEN represents a stock of added interest, as 2011 may be a transformational year for the Company with the potential approval of b. vedotin in both HL and ALCL in 2H11. We remain highly impressed by the ORR rate, CR rate, and durable responses in these hard-to-treat patient populations: the quality of the data decrease the regulatory and commercialization risk going forward."

Needham & Company maintains a "Buy" rating on Seattle Genetics, which closed Wednesday at $15.54, up $0.20, or 1.30 percent. Needham has a price target of $18 on them.

Seattle Genetics' (NASDAQ:SGEN) Vedotin Risk Appears to Shrink

Risk related to Seattle Genetics' (NASDAQ:SGEN) b. Vedotin seem to have lowered after reports on the ORR for its trial were released.

Needham said, "The data from the pivotal trial of b. vedotin in r/r HL were featured in an ASH Meeting press release over the weekend and highlighted at a company meeting in Orlando. Previously, the Company had reported the ORR for its pivotal trial of b. vedotin in HL was 75% by independent central review. New information from this trial of 102 patients reported at the ASH Meeting included: (1) 34% complete response rate; (2) overall median duration of response 29 weeks by investigator review, and median duration of response not met for CRs at > 1 year of follow-up; (3) 94% of patients with tumor reductions; and (4) a dropout rate of 20% due to adverse side effects. Furthermore, a preview of the ALCL pivotal data expected Tuesday showed an ORR of 87% (57% CR) by independent review. Based on these data, Seattle Genetics announced plan to submit a BLA for b. vedotin for both r/r HL and r/r ALCL in 1Q11, following recent FDA discussions, with plans to submit a MAA in 1H11 by partner Millennium/Takeda...We remain highly impressed by the ORR rate, CR rate, and durable responses in these hard-to-treat patient populations: the quality of the data decrease the development and commercialization risk going forward."

Needham maintains their "Buy" rating on Seattle Genetics, which closed Monday at $15.23, dropping $0.64, or 4.03 percent. Needham has a price target of $18 on the company.